Raludotatug Deruxtecan

Phase 2Antibody–drug conjugate

Merck & Co.

Raludotatug Deruxtecan is one of 69 biologic programs targeting Intestinal Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Intestinal CancerActive, not recruiting

Solid TumorActive, not recruiting

Ovarian Cancer RecurrentRecruiting

Intestinal CancerPhase 2

Active, not recruiting

Solid TumorPhase 2

Active, not recruiting

Ovarian Cancer RecurrentPreclinical

Recruiting

Competition

Competitive Landscape

348 competitors in Solid Tumor

#DrugCompanyPhaseTrials

Raludotatug Deruxtecan

Merck & Co.

Phase 2

1 2

Zejula

GGlaxo Dba Glaxosmithkline

Preclinical

2 3

Epivir

GGlaxo Dba Glaxosmithkline

Preclinical

1 4

Navmi

SSummit Therapeutics

Preclinical

1 5

Proleukin

IIovance Biotherapeutics, Inc.

Preclinical

1 6

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 7

Carboplatin AUC-5

Merck & Co.

Preclinical

1 8

IL-2

FFate Therapeutics

Preclinical

2 9

Interleukin 2

EEssen Biotech

Preclinical

2 10

GT201

GGrit Biotechnology

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2029

Phase 2Active, not recruiting

Intestinal Cancer

NCT06864169

Q4 2029

Phase 2Active, not recruiting

Solid Tumor

NCT06660654

Q1 2031

PreclinicalRecruiting

Ovarian Cancer Recurrent

NCT06843447

Q1 2032

Phase 2Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06780085

Clinical

Trials by Indication[1]

Intestinal Cancer1 trial

A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT06864169·160 enrolled

Ovarian Cancer Recurrent1 trial

A Phase 1b/2 Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan With or Without Other Anticancer Investigational Agents in Participants With Advanced High-Grade Serous or High-Grade Endometrioid Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (REJOICE-Ovarian02)

Recruiting· Merck & Co. logo

Merck & Co.·Preclinical·NCT06843447·605 enrolled

Carcinoma, Non-Small-Cell Lung1 trial

KEYMAKER-U01 Substudy 01H: A Phase 2, Randomized, Umbrella Study With Rolling Arms of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC)

Recruiting· Merck & Co. logo

Merck & Co.·Phase 2·NCT06780085·96 enrolled

Solid Tumor1 trial

REJOICE-PanTumor01: A Phase 2, Multicenter, Open-Label, Pan-Tumor Trial to Evaluate Efficacy and Safety of Raludotatug Deruxtecan (R-DXd) in Participants With Advanced/Metastatic Solid Tumors

Active, not recruiting· Daiichi Sankyo logo

Daiichi Sankyo·Phase 2·NCT06660654·335 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Raludotatug Deruxtecan. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Raludotatug Deruxtecan compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Raludotatug Deruxtecan. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Merck & Co. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Antibody–drug conjugate[2]
Highest Phase: Phase 2[1]
Company: Merck & Co.

Raludotatug Deruxtecan

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2029

Q4 2029

Q1 2031

Q1 2032

Trials by Indication[1]

Intestinal Cancer1 trial

Ovarian Cancer Recurrent1 trial

Carcinoma, Non-Small-Cell Lung1 trial

Solid Tumor1 trial

References

Drug Info

Quick Facts

Related News